Status:
TERMINATED
Substance Use in Elderly Individuals: Brain and Cognitive Correlates and the Effect of Psychotherapy
Lead Sponsor:
Prof. Dr. med. Egemen Savaskan
Conditions:
Substance Use Disorder
Eligibility:
All Genders
65+ years
Phase:
NA
Brief Summary
The prevalence of addictive disorders in old age is increasing. Age specific and appropriate therapeutic concepts tailored to in-patients thus represent a promising approach for the future. The invest...
Detailed Description
The prevalence of addictive disorders in old age is increasing. Age specific and appropriate therapeutic concepts tailored to inpatients thus represent a promising approach for the future. The investi...
Eligibility Criteria
Inclusion
- Subjects aged 65 or above with, according to WHO-ASSIST V3.0, a hazardous consumption of alcoholic beverages and / or benzodiazepines and / or non-benzodiazepine hypnotics (zolpidem, zopiclone, zaleplon)
- The subjects must be able to understand verbal and written information about the study flow and content and to give their written consent.
- The subjects must be able to understand and perform verbal and written tasks (cognitive tests / questionnaires)
Exclusion
- Taking medication that could affect cognition outside of benzodiazepines and / or non-benzodiazepine hypnotics (zolpidem, zopiclone, zaleplon).
- Drug treatments with anxiolytics (benzodiazepines) as part of an ongoing drug-assisted detoxification
- Taking antidepressant medication
- Taking sleep-inducing substances (for example Dipiperon®, Trittico®, Valverde Sleep® or Valverde Entspannung®)
- Taking other anxiolytic active substances (for example, pregabalin, Opipramol). The use of medication is allowed to treat somatic diseases.
- Use of drugs or substance dependence. Except for alcohol, benzodiazepines and non-benzodiazepine hypnotics (zolpidem, zopiclone, zaleplon)
- Diseases which prevent the subject from giving consent for this study or which impair cooperation in the investigation.
- Severe and / or unstable physical illness: severe depression, severe mania, delirium, severe cognitive impairment (mini-mental status test \< 20/30 points), dementia of the Alzheimer type or other dementias, multiple sclerosis, clinically manifest structural brain damage (eg cerebral hemorrhage, brain tumors, MRI findings by Schulthess clinic)
- Heavily impaired vision and eye diseases
- Additional exclusion criteria for part 2 of the study:
- Pacemaker, implantable cardioverter defibrillator (ICD), neurostimulator, aneurysm clip, prosthetic heart valve, valve prosthesis, metal prosthesis
- Clips after surgery, metallic bone plates, artificial joints, metal fragments in the body, professional in the metal processing industry, non-removable piercing, ferruginous tattoo ink
- Pregnancy
- Claustrophobia
- Use of alcohol or other consciousness-altering substances within 24 hours prior to the MRI scan (exceptions: see "exclusion criteria")
Key Trial Info
Start Date :
February 2 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 15 2017
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT02835144
Start Date
February 2 2017
End Date
November 15 2017
Last Update
November 21 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gerontopsychiatrisches Zentrum Hegibach
Zurich, Switzerland, 8032